Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Analysts maintain a “Moderate Buy” consensus on Denali Therapeutics, with 14 buy, 2 hold and 1 sell rating among 17 analysts. The average 12-month price target is $35.85, above the reported share price of $23.26.
• Recent analyst actions were generally positive: Deutsche Bank raised its target to $35 and UBS increased its objective to $34, although Bernstein reiterated a hold and Weiss Ratings maintained a sell rating.
• Denali reported a quarterly loss of $0.68 per share, missing estimates of a $0.51 loss, while revenue of $3.60 million exceeded forecasts. Institutional investors own 92.92% of the company, and an insider recently sold 2,857 shares at $25.07 each.

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seventeen ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and fourteen have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $35.8462.

DNLI has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Denali Therapeutics from $31.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, July 16th. Sanford C. Bernstein restated a "hold" rating on shares of Denali Therapeutics in a report on Monday, June 22nd. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Denali Therapeutics in a research report on Friday, July 17th. Wall Street Zen upgraded Denali Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Finally, UBS Group boosted their price objective on Denali Therapeutics from $25.00 to $34.00 and gave the stock a "buy" rating in a research report on Friday, August 7th.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the transaction, the insider directly owned 281,763 shares of the company's stock, valued at $7,063,798.41. The trade was a 1.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 9.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Denali Therapeutics

Several hedge funds have recently modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Denali Therapeutics during the second quarter worth $26,000. Headlands Technologies LLC bought a new stake in Denali Therapeutics in the 2nd quarter valued at $26,000. Global Retirement Partners LLC bought a new stake in Denali Therapeutics in the 2nd quarter valued at $28,000. Johnson Financial Group Inc. bought a new stake in Denali Therapeutics in the 3rd quarter valued at $29,000. Finally, State of Wyoming acquired a new stake in Denali Therapeutics in the 2nd quarter worth $29,000. 92.92% of the stock is owned by institutional investors.

Denali Therapeutics Trading Down 2.1%

Shares of DNLI stock opened at $23.26 on Wednesday. Denali Therapeutics has a 12 month low of $12.58 and a 12 month high of $27.30. The company has a market cap of $3.72 billion, a PE ratio of -8.19 and a beta of 1.01. The company has a quick ratio of 8.32, a current ratio of 8.37 and a debt-to-equity ratio of 0.01. The business's 50 day moving average is $24.58 and its two-hundred day moving average is $21.78.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million for the quarter, compared to analyst estimates of $2.15 million. During the same period last year, the firm earned ($0.72) EPS. Equities analysts predict that Denali Therapeutics will post -2.67 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source